The selective P-TEFb inhibitor CAN508 targets angiogenesis
Jazyk angličtina Země Francie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
21777997
DOI
10.1016/j.ejmech.2011.06.035
PII: S0223-5234(11)00511-3
Knihovny.cz E-zdroje
- MeSH
- azosloučeniny farmakologie MeSH
- fosforylace MeSH
- genetická transkripce účinky léků MeSH
- inhibitory proteinkinas farmakologie MeSH
- kultivované buňky MeSH
- lidé MeSH
- messenger RNA genetika MeSH
- patologická angiogeneze prevence a kontrola MeSH
- pozitivní transkripční elongační faktor b antagonisté a inhibitory MeSH
- pyrazoly farmakologie MeSH
- RNA-polymerasa II metabolismus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- azosloučeniny MeSH
- CAN 508 MeSH Prohlížeč
- inhibitory proteinkinas MeSH
- messenger RNA MeSH
- pozitivní transkripční elongační faktor b MeSH
- pyrazoly MeSH
- RNA-polymerasa II MeSH
Small molecule inhibitors of cyclin-dependent kinases (CDK) have been developed as anticancer drugs with cytostatic and cytotoxic properties, but some of them have also been shown to limit angiogenesis. Here, we report that the 3,5-diaminopyrazole CAN508 inhibits endothelial cell migration and tube formation. In addition, it reduces phosphorylation of the C-terminus of RNA polymerase II and inhibits mRNA synthesis in endothelial cells, in accordance with previous observations that it has high selectivity towards the positive transcriptional regulator P-TEFb. Moreover, CAN508 reduces expression of vascular endothelial growth factor by several human cancer cell lines. The findings suggest that P-TEFb may be an attractive target for anti-angiogenic therapy.
Citace poskytuje Crossref.org
Modification of Boc-Protected CAN508 via Acylation and Suzuki-Miyaura Coupling
Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target